These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 12169743)
1. Moving from CFC aerosol to HFA aerosol or dry powder inhalers: what do patients think? Hartung TK; Allbutt H; Dewar M; Innes JA; Crompton GK Respiration; 2002; 69(4):314-9. PubMed ID: 12169743 [TBL] [Abstract][Full Text] [Related]
2. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Huchon G; Hofbauer P; Cannizzaro G; Iacono P; Wald F Eur Respir J; 2000 Apr; 15(4):663-9. PubMed ID: 10780756 [TBL] [Abstract][Full Text] [Related]
4. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. Boccuzzi SJ; Wogen J; Roehm JB Clin Ther; 2000 Feb; 22(2):237-47. PubMed ID: 10743983 [TBL] [Abstract][Full Text] [Related]
5. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chrousos GP; Ghaly L; Shedden A; Iezzoni DG; Harris AG Chest; 2005 Jul; 128(1):70-7. PubMed ID: 16002918 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD. Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820 [TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Fireman P; Prenner BM; Vincken W; Demedts M; Mol SJ; Cohen RM Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. Lipworth BJ; Jackson CM Br J Clin Pharmacol; 1999 Dec; 48(6):866-8. PubMed ID: 10594492 [TBL] [Abstract][Full Text] [Related]
12. Medical aerosol propellant interference with infrared anaesthetic gas monitors. Levin PD; Levin D; Avidan A Br J Anaesth; 2004 Jun; 92(6):865-9. PubMed ID: 15121726 [TBL] [Abstract][Full Text] [Related]
13. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability. Brindley A J Allergy Clin Immunol; 1999 Dec; 104(6):S221-6. PubMed ID: 10588978 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002 [TBL] [Abstract][Full Text] [Related]
15. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial. Escribano A; Tutuncu A; Löhr I; Carlholm M; Polanowski T Curr Med Res Opin; 2006 Jun; 22(6):1085-92. PubMed ID: 16846541 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007 [TBL] [Abstract][Full Text] [Related]
18. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol. Peyron ID; Britto IL; Benissan LB; Tardieu BZ Respir Med; 2005 Apr; 99 Suppl A():S20-30. PubMed ID: 15777605 [TBL] [Abstract][Full Text] [Related]
19. Short-term lower leg growth in 5- to 11-year-old asthmatic children using beclomethasone dipropionate inhalers with chlorofluorocarbon or hydrofluoroalkane propellants: a 9-week, open-label, randomized, crossover, noninferiority study. Wolthers OD; Walters EG Clin Ther; 2011 Aug; 33(8):1069-76. PubMed ID: 21784529 [TBL] [Abstract][Full Text] [Related]
20. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Dusser D; Vicaut E; Lefrançois G; Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]